Shares of Glenmark Pharmaceuticals Ltd were trading in the red and 1% lower on Thursday, 27 February, despite the company’s US-based subsidiary announcing launching its epinephrine injection USP, a medication used to treat severe allergic responses.

An injection comprising 10 mg/10 mL (1 mg/mL) has been introduced in a multiple-dose container.

Glenmark said in a stock exchange filing that the newly released drug is bioequivalent to the reference-listed drug made by BPI Labs, LLC, and therapeutically equivalent.

This launch gives Glenmark a 180-day FD&C Act Competitive Generic Therapy (CGT) exclusivity.

Epinephrine is used to treat severe allergic reactions and sudden asthma episodes. Additionally, it can help regulate low blood pressure and lower heart rate. By avoiding allergic reactions, it reduces symptoms including breathing issues and swelling of the face, lips, and throat.

According to IQVIA sales statistics, the Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) market as a whole earned sales of around $42.7 million for the 12 months that ended in December 2024.

With Glenmark’s entry into this industry, healthcare organizations should be able to replace the present reference product with a high-quality, cost-effective alternative.

Marc Kikuchi, President & Business Head of North America, said, “We are excited to announce the launch of epinephrine injection USP, 10 mg/10 mL (1 mg/mL) multiple-dose Vial, growing our portfolio of products within the institutional channel while also strengthening our commitment to bringing high-quality and affordable alternatives to patients.”

International pharmaceutical company Glenmark is a major player in the over-the-counter (OTC), generic, and branded sectors and is committed to research. Therapeutic areas like dermatology, respiratory care, and oncology are the company’s areas of expertise.

With 11 excellent manufacturing facilities dispersed over four continents and activities in more than 80 countries, Glenmark continues to expand its presence by developing innovative and affordable pharmaceutical solutions.

At 1:39 pm, the shares of Glenmark Pharma were trading 1.53% lower at Rs 1,296.15 on NSE.

Sonata Glenmark Pharmaceuticals Ltd? Let the Analyst Guide You.

Tired of guessing stocks to trade in daily?
Unicorn Signals empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Unicorn Signals app today and take control of your investments!